This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

  • Tickers in this article:
  • RTRX

Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.

09/30/14 - 05:53 PM EDT

Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today

  • Tickers in this article:
  • CPRX

Catalyst Pharmaceutical Partners (CPRX) shares rose after ROTH Capital raised the company's price target to $6 from $5 and reiterated its 'buy' rating.

09/30/14 - 03:09 PM EDT

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

  • Tickers in this article:
  • RTRX

Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.

09/30/14 - 05:53 PM EDT

Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today

Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today

  • Tickers in this article:
  • CPRX

Catalyst Pharmaceutical Partners (CPRX) shares rose after ROTH Capital raised the company's price target to $6 from $5 and reiterated its 'buy' rating.

09/30/14 - 03:09 PM EDT

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?

09/30/14 - 09:49 AM EDT

Why Walgreen Shares Are Moving Higher Despite OK Q4 Earnings

  • Tickers in this article:
  • WAG

Prescription drug sales helped Walgreen post its best quarterly sales figures in three years.

09/30/14 - 09:43 AM EDT

Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug

Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug

For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.

09/30/14 - 07:20 AM EDT

Epirus CEO: Prepare for Biosimilar Breakout as Patent Cliff Nears

  • Tickers in this article:
  • EPRS

The biosimilar market will soon be booming as over $80 billion worth of drugs go off patent in the next 7 years, said Amit Munshi, CEO of Epirus Biopharmaceuticals.

09/29/14 - 04:29 PM EDT

Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios

Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios

Biotech columnist Adam Feuerstein answers readers' questions about health care.

09/26/14 - 07:00 AM EDT

Gilead Sciences' Next-Generation HIV Drug Hits the Mark

Gilead Sciences' Next-Generation HIV Drug Hits the Mark

  • Tickers in this article:
  • GILD

TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.

09/24/14 - 10:30 AM EDT

Why Sarepta Therapeutics (SRPT) Stock Is Gaining Today

Why Sarepta Therapeutics (SRPT) Stock Is Gaining Today

  • Tickers in this article:
  • SRPT

Sarepta Therapeutics (SRPT) shares are up after analysts at Credit Suisse initiated coverage with a 'buy' rating on Wednesday.

09/24/14 - 10:23 AM EDT

Why Acorda Therapeutics (ACOR) Stock Is Rising Today

Why Acorda Therapeutics (ACOR) Stock Is Rising Today

  • Tickers in this article:
  • ACOR

Acorda Therapeutics (ACOR) shares are up double digits after announcing that it was buying Civitas Therapeutics for $525 million.

09/24/14 - 09:36 AM EDT

Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor

Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor

Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.

09/22/14 - 07:48 PM EDT

Merrimack Does Well to License Marginal Cancer Drug to Baxter

Merrimack Does Well to License Marginal Cancer Drug to Baxter

Baxter has a hunger for cancer drugs with hair.

09/24/14 - 08:14 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs